Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75Science kürt Immuntherapie gegen Krebs 2013 zum „Breakthrough of the Year“
/in Externe Meldungen /von IOZKBispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2013-02-01 / BioDrugs 2013 Feb;27(1):35-53Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44TV-Beitrag-National Institutes of Health: Will Dendritic Cell Subsets help us address the challenges of Cancer, Autoimmunity and Viral Diseases?
/in Externe Meldungen /von IOZKAnalysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2012-01-01 / Methods Mol. Biol. 2012;797:177-204Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98Nobelpreis für Medizin 2011 für die Entdeckung grundlegender immunologischer Mechanismen
/in Externe Meldungen, IOZK Meldungen /von IOZK
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution